WallStreetZenWallStreetZen

NASDAQ: DYN
Dyne Therapeutics Inc Stock

Overview
ForecastEarningsDividendOwnership
$25.44-0.41 (-1.59%)
Updated Apr 15, 2024
DYN Price
$25.44
Fair Value Price
$28.24
Market Cap
$2.09B
52 Week Low
$6.40
52 Week High
$30.27
P/E
-6.44x
P/B
22.84x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$235.94M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.81
Operating Cash Flow
-$188M
Beta
1.37
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A

DYN Overview

Dyne Therapeutics, Inc. is a biotechnology company focusing treatments for genetically driven muscle diseases in the U.S. Its products and programs target myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases. Dyne Therapeutics was incorporated in 2017 and is headquartered in Waltham, MA.

Zen Score

–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how DYN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

DYN ($25.44) is undervalued by 9.92% relative to our estimate of its Fair Value price of $28.24 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
DYN ($25.44) is not significantly undervalued (9.92%) relative to our estimate of its Fair Value price of $28.24 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
DYN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more DYN due diligence checks available for Premium users.

Be the first to know about important DYN news, forecast changes, insider trades & much more!

DYN News

Valuation

DYN fair value

Fair Value of DYN stock based on Discounted Cash Flow (DCF)
Price
$25.44
Fair Value
$28.24
Undervalued by
9.92%
DYN ($25.44) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
DYN ($25.44) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
DYN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

DYN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-6.44x
Industry
14.94x
Market
41.94x

DYN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
22.84x
Industry
5.88x
DYN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

DYN's financial health

Profit margin

Revenue
$0.0
Net Income
-$66.6M
Profit Margin
0%
DYN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$165.1M
Liabilities
$73.8M
Debt to equity
0.81
DYN's short-term assets ($129.38M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DYN's short-term assets ($129.38M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DYN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
DYN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$35.0M
Investing
$26.2M
Financing
$147.0k
DYN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

DYN vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
DYN$2.09B-1.59%-6.44x22.84x
KROS$2.08B-1.59%-11.09x6.25x
BEAM$2.10B-0.89%-14.94x2.14x
KYMR$2.10B-3.34%-13.65x5.32x
DNA$2.04B-5.94%-2.07x1.86x
View Top Biotech Stocks

Dyne Therapeutics Stock FAQ

What is Dyne Therapeutics's quote symbol?

(NASDAQ: DYN) Dyne Therapeutics trades on the NASDAQ under the ticker symbol DYN. Dyne Therapeutics stock quotes can also be displayed as NASDAQ: DYN.

If you're new to stock investing, here's how to buy Dyne Therapeutics stock.

What is the 52 week high and low for Dyne Therapeutics (NASDAQ: DYN)?

(NASDAQ: DYN) Dyne Therapeutics's 52-week high was $30.27, and its 52-week low was $6.40. It is currently -15.95% from its 52-week high and 297.5% from its 52-week low.

How much is Dyne Therapeutics stock worth today?

(NASDAQ: DYN) Dyne Therapeutics currently has 81,958,068 outstanding shares. With Dyne Therapeutics stock trading at $25.44 per share, the total value of Dyne Therapeutics stock (market capitalization) is $2.09B.

Dyne Therapeutics stock was originally listed at a price of $23.90 in Sep 17, 2020. If you had invested in Dyne Therapeutics stock at $23.90, your return over the last 3 years would have been 6.44%, for an annualized return of 2.1% (not including any dividends or dividend reinvestments).

How much is Dyne Therapeutics's stock price per share?

(NASDAQ: DYN) Dyne Therapeutics stock price per share is $25.44 today (as of Apr 15, 2024).

What is Dyne Therapeutics's Market Cap?

(NASDAQ: DYN) Dyne Therapeutics's market cap is $2.09B, as of Apr 16, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Dyne Therapeutics's market cap is calculated by multiplying DYN's current stock price of $25.44 by DYN's total outstanding shares of 81,958,068.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.